MedTrace Logo

Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer

NCT03937141 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2022-01-03

Study results available
· View outcomes & findings →

Summary

ADU-CL-20 is an open-label, multicenter Phase 2 clinical trial to evaluate the efficacy and safety of intratumoral ADU-S100 (also referred to as MIW815) administered with pembrolizumab in the first-line setting. The population will consist of adults with PD-L1 positive recurrent or metastatic HNSCC.

Conditions

  • Metastatic Head and Neck Cancer
  • Recurrent Head and Neck Cancer

Interventions

DRUG

ADU-S100

intratumoral

Sponsors & Collaborators

  • Chinook Therapeutics, Inc. (formerly Aduro)

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-26
Primary Completion
2021-05-10
Completion
2021-06-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03937141 on ClinicalTrials.gov